Medgenics takes option on pediatric onset IBD prods from Kyowa Hakko
US firm Medgenics (NYSE: MDGN) has entered into a collaboration with Japan’s Kyowa Hakko Kirin (TYO: 4151) for the development and commercialization of the latter's first-in-class anti-LIGHT monoclonal antibody.
The anti-LIGHT monoclonal antibody is a Phase II-ready biologic with available clinical supply. Medgenics plans to initiate a signal finding study testing the drug in severe pediatric onset inflammatory bowel disease (IBD) in collaboration with Robert Baldassano, director of the Center for Pediatric IBD at The Children's Hospital of Philadelphia (CHOP).
"IBD is a distinct and severe genetic disease in children, with very limited treatment options available," said Dr Baldassano, adding: "I am pleased to see Medgenics and Kyowa Hakko Kirin come together to advance the development of this program for children with this severe, genetically driven disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze